Metastatic Castration-Resistant Prostate Cancer

The FDA announced several regulatory actions.

In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses data from the TRITON3 trial presented at ASCO Genitourinary Cancers Symposium.

In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses data presented from the TALAPRO-2 trial, presented at ASCO Genitourinary Cancers Symposium.

In this video, Atish Choudhury, MD, a medical oncologist at Dana-Farber Cancer Institute, discussed the treatment of metastatic castration-resistant prostate cancer with radium-223 in patients with homologous recombination deficiency.

SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for certain men with metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.

A randomized phase 3 trial that assessed rucaparib for certain men with advanced prostate cancer met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.

Phase 3 studies of pembrolizumab — with chemotherapy for metastatic castration-resistant prostate cancer and with lenvatinib for unresectable liver cancer — did not meet primary endpoints of survival, according to the agent’s manufacturer.

First-line abiraterone acetate for metastatic castration-resistant prostate cancer conferred longer OS among Black men compared with non-Hispanic white men, according to study results published in JAMA Network Open.

The addition of ipatasertib to standard therapy benefited certain men with metastatic castration-resistant prostate cancer, according to topline data released by the agent’s manufacturer.

The FDA approved olaparib for treatment of certain men with metastatic castration-resistant prostate cancer.